Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: An interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK

<p><strong>Background:</strong><br /> A safe and efficacious vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), if deployed with high coverage, could contribute to the control of the COVID-19 pandemic. We evaluated the safety and efficacy of the ChA...

Full description

Bibliographic Details
Main Authors:	Voysey, M, Clemens, SAC, Madhi, SA, Weckx, LY, Folegatti, PM, Aley, PK, Angus, B, Baillie, VL, Barnabas, SL, Bhorat, QE, Bibi, S, Briner, C, Cicconi, P, Collins, AM, Colin-Jones, R, Cutland, CL, Darton, TC, Dheda, K, Duncan, CJA, Emary, KRW, Ewer, KJ, Fairlie, L, Faust, SN, Feng, S, Ferreira, DM, Finn, A, Goodman, AL, Green, CM, Green, CA, Heath, PT, Hill, C, Hill, H, Hirsch, I, Hodgson, SHC, Izu, A, Jackson, S, Jenkin, D, Joe, CCD, Kerridge, S, Koen, A, Kwatra, G, Lazarus, R, Lawrie, AM, Lelliott, A, Libri, V, Lillie, PJ, Mallory, R, Mendes, AVA, Milan, EP, Minassian, AM, Lambe, T, Pollard, AJ
Other Authors:	Oxford COVID Vaccine Trial Group
Format:	Journal article
Language:	English
Published:	Elsevier 2020

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: An interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK

Similar Items